Showing results (131-140 of 188) with videos related to
Sort By:
Pageof 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2008
Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B studyPeter Paschka, Guido Marcucci, Amy S Ruppert, et al.Skin Pharmacology and Physiology|March 11, 2010
In vitro sun protection factor: still a challenge with no final answerM Rohr, E Klette, S Ruppert, et al.Leukemia Research|July 23, 2022
Patient-driven research: Initial results from a prospective health-related quality of life study performed at the request of patients living with hairy cell leukemiaMirela Anghelina, Michelle J Naughton, Qiuhong Zhao, et al.Blood|March 9, 2006
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461, Sherif S Farag, Kellie J Archer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B studyGuido Marcucci, Krzysztof Mrózek, Amy S Ruppert, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 24, 2022
Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I StudyDeborah M Stephens, Ying Huang, Amy S Ruppert, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 23, 2008
Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemiaLeslie A Andritsos, Amy J Johnson, Gerard Lozanski, et al.Blood Advances|April 10, 2024
Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101Tracy T Batchelor, Sharmila Giri, Amy S Ruppert, et al.Blood|April 2, 2008
High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) studyChristian Langer, Michael D Radmacher, Amy S Ruppert, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2008
Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B StudyGuido Marcucci, Kati Maharry, Michael D Radmacher, et al.Pageof 19